According to the Zhitong Finance App, Xintai Healthcare (02291) announced its 2023 results, with revenue of about 326 million yuan, an increase of 31.6% over the previous year. R&D expenses increased 14.3% year over year to 61.6 million yuan, and profit attributable to company owners was 151.5 million yuan, turning a loss into a profit year over year. Adjusted net profit increased 55.4% year over year to $173 million, with earnings of $0.44 per share and a final dividend of $0.57 per share (tax included).
As of the date of this announcement, the Group has a total of 22 blockers and accessories products already on the market, 9 products under registration review and preparation for registration, and 24 products under development, such as blockers, heart valves and surgical accessories, and mechanical circulation aids, which are in various stages of development.